JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that its Board of Directors has authorized the Company to repurchase, including through one or more subsidiaries, up to an aggregate of $600 million of its ordinary shares/ADRs and convertible debentures of its finance subsidiaries. The repurchase program, Teva's third such program in recent years, is designed to enhance shareholder value and to offset dilution due to share issuances under the Company's employee compensation plans.
